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Results: From a sample of 522 patients admitted to an acute pain
27 reliefand palliative care unit in a period of 13 months, 100 patients
with abdominal disease were available. The mean age was 65.3
ro years (SD + il.4); of the 100 patients, 45 (45%) were males. The
mean Karnofsky status was 47.7 (SD + 11.1). At admission (T0),
1 r 67 patients (61%) had background pain with mean pain intensity ofJr 4.9 (SD + 1.6). Sixty-one patients of those with background pain
(91%) had superimposed and well-distinguished pain flares. After33 analgesic optimization (T1), the mean bàckground pain intensity
was 1.7 (SD L 1.2), and 55.2o/o of patients had BTcp episodes. The
35 difference with T0 was significanr (p < 0.0005).
1a Conclusions: This preliminary study provides new insights on ther t characteristics of BTcP in a subclass of patients with abdominal
disease. It has been estimated that about 55% of patients with well-39 controlled background pain will develop BTcp episodes. This
percentage was higher (about 90%) in patients who presented with
41 uncontrolled background pain, underlying the need to better
characterize patients with BTcP, only after a careful optimization
43 ol basal pain, as considered by the definition ol BTcp.
tE Key Words: cancer pain, breakthrough pain, abdominal pain,+J epidemiology,opioids
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49
/\ bdominal pain is common in patients with cancer. In a5l Asurvey on prevalence, causes, and mechanisms of painin advanced cancer patients followed up at home,53 abdominal pain has beèn found to have an-incidence of
55
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Objective: Characterization ol breakthrough cancer pain (BTcP) in
patients with abdominal cancer is lacking. The aim of this study
was to assess the characteristics ol BTcP in patients with abdominal
cancer pain.
Patients and Methods: In an observational cohort study, lrom a
consecutive sample of patients admitted to a pain relief and sup-
portive care unit for a period of 13 months, patients with
abdominal disease due to cancer, including primary cancer or
metastases, were assessed lor the presence of chronic abdominal
pain; its mechanism, intensity ol background pain, and pain flares,
which were distinguishable from the baseline pain, were recorded.
Patients presenting with pain flares were assessed regarding the
causes and the possible factors associated with it. Patients were
reassessed when background pain control was considered optimal.
45Yo. Two third of patients presented a visceral pain,
although mixed pain syndromes were observed in more
than half of these patients.l Pain may arise lrom different
causes.r Primary tumors or metastases may involve luminal
organs of the gastrointestinal or genitourinary tracts, the
parenchymal organs, the peritoneum, or the retroperitoneal
soft tissues. Obstruction of hollow viscus, including intes-
tine, biliary tract, and ureters produces typical visceral
nociceptive pain syndromes. When peritoneum, abdominal
wall, pelvic organs, and retroperitoneal tissues are involved
by tumor masses, mixed nociceptive and neuropathic
mechanisms develop if both somatic structures and nerves
are damaged. Other than the tumor involvement, oncologic
treatments may cause devastating anatomic and functional
changes. A number of chemotherapeutic regimens are
commonly administered even in the advanced stage of
disease. Neurotoxic chemotherapy, external beam radia-
tion, radiation implants, pelvic exenteration, or other
interventional procedures produce serious local problems,
and pain is the most.frequent symptom reported as a con-
sequence of therapy.l
Breakthrough cancer pain (BTcP) has been defined as
a transitory increase in pain intensity that occurs either
spontaneously or in relation to a specific predictable or
unpredictable trigger, despite relatively stable3 and ade-
quately controlled background pain.a BTcP is a common
problem in patìents with cancer and is associated with
significant morbidity in this group of patients. BTcp has a
negative impact on both quality of life (including activities
of daily living, sleep, social relationships, and mood) and
medical outcomes.s In different surveys, 50% to 90"A oî
cancer patients with pain have been reported to experience
intermittent flares of their pain, although using different
definitions and methodology.6 In a general population,
patients with visceral neoplasms or visceral pain had a
lower likelihood of BTcP./ However, patients with
abdominal cancer may develop other mechanisms of pain.
Information about epidemiology and pathophysiology of
pain exacerbation in patielts with abdominal cancer pain is
poor and characterlzation of this type of BTcP is lacking.a
The aim of this study was to assess the characteristics of
BTcP in patients with abdominal cancer pain.
PATIENTS AND METHODS
From a consecutive sample of patients admitted to a
pain relief and supportive care unit for a period of 7
months, patients with abdominal disease duè to cancer,
including primary cancer or metastases, were selected.
Patients with cognitive impairment, unable to answer the
questions posed lor the pain assessment, were excluded.
Patients who had extra-abdominal disease-producing pain,
concomitant bone involvement, or patients severely ill with
a survival of <2 weeks were also excluded. Patients
receiving radiotherapy or who had changed their anticancer
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treatment in the previous month were excluded. Written
informed consent from patients and ethical committee
approval lrom the University of Palermo were obtained.
At admission (T0), information with regard to the
presenc€ of chronic abdominal pain, its mechanism, intensity
of background pain, and pain flares, which were clearly dis-
tinguishable from the baseline pain, were obtained. This
information was based on the previous 24 hours before
admission. Paìn mechanisms were diagnosed according to the
clinical history, presentation, and imaging studies; pain
intensity was assessed using a numerical scale from 0 to 10.
Characteristics of patients were recorded, including age, sex,
primary cancer, site of pain, intensity ol background pain,
and analgesics used for background pain. Patients presenting
with pain flares were assessed regarding the causes and the
possible factors associated with it. Data regarding charac-
teristics, causes, and frequency of BTcP, as well as onset,
duration, intensity, medications used for BTcP, and level of
satisfaction with this treatment (poor, acceptable, good, and
very good) were recorded. Patients were treated according to
the department policy. According to the modality and char-
acteristics of BTcP presentation, an analgesic treatment was
planned, including the optimization of basal opioid therapy
with the aim to achieve an adequate analgesia. Alter estab-
lishing an around-the-clock opioid medication able to pro-
duce an acceptable analgesia, with a pain intensity <4/10,
without relevant adverse effects, patients were encouraged to
call when their pain got severe and when superimposed epi-
sodes of BTcP occurred. The choice of opioids for back-
ground pain and BTcP was on the basis of clinical judgment,
arcording to different factors, including the patient's char-
acteristics, clinical needs, patients' compliance, and prefer-
ence. Written orders for BTcP, including drugs and doses to
be administered when pain gets severe enough are routinely
mentioned in the therapy chart. Department policy sugfiests
that the dose to be given is proportional to the dose admin-
istered for background analgesia.6 Patients were reassessed
when background pain control was considered optimal (T1),
mainly the day before discharge.
Statistics
The initial part of the study included 50 patients in a
period of 7 months. This period was considered insufficient
lor recruiting a large number of subclass of patients with
abdominal cancer disease. A sample of 100 patients was
deemed to be appropriate for the purpose of this study, to
have a sufficient epidemiological value, and the study was
prolonged with this purpose. The sample size of 100 patients
was able to detect a 30"A difference in intragroup pain
intensity score at a significance level of a type 1 error of
0.05, considering B type 2 error: 0.8. The within-group SD
is assumed to be 3 with a percentage of missing dala oÎ 20ok.
A11 continuous data are expressed as a mean t SD of
the mean. Statistical analysis of quantitative data, including
descriptive statistics, was perlormed for all the items.
Frequèncy analysis was performed using the Pearson 12 test
and the McNemar test, as needed. The paired samples The
Student t test and the paired Wilcoxon signed-rank test
were used to compare parametric and nonparametric vari-
ables, respectively, at different intervals. Data were ana-
lyzed by the Epi Info software, version 3.2.2 (Centers for
Disease Control and Prevention) and by SPSS Software
14.0 version (SPSS Inc., Chicago, IL). All P values were
2-sided, and P values <0.05 were considered statistically
significant.
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RESULTS
From a consecutive sample oî 522 patients admitted to
an acute pain relief and palliative care unit in a period of 1 3
months, 100 patients with abdominal disease were available
lor the study assessment. The epidemiological character-
istics of the selected population are described in Table 1.
At admission (T0), 67 patients (67%)had background
pain. The mechanisms were: 30 pure visceral pain, 11 vis-
ceral-neuropathic pain, and 26 visceral somatic pain. At
admission, the mean intensity of background pain intensity
was 4.9 (SD + 1.6). Fifty-four (80.6%) patients were
receiving analgesic drugs for background analgesia
(Table 2).
The causes ol BTcP identified at T0 are described
in Table 3. Sixty-one patients of those with background
pain (91%) had superimposed and well-distinguished pain
flares with a mean intensity of 8.0 (SD + 0.9). The back-
ground pain intensity in this group of patients was 5.1
(SD * 1.5). The difference between BTcP intensity and
background pain intensity reported in all patients was sig-
nificant (P : < 0.0005). The mean number ol episodes per
day was 2.6 (SD + 1.0). In 13 patients, the onset was
< 1 minute, in 28 patients the onset was 1 to 5 minutes, in
i4 patients was 5 to 10 minutes, and in 6 patients the onset
was > 10 minutes. The duration of BTcP was < 5 minutes
in 1 patient, 5 to 10 minutes in 18 patients, 10 to 30 minutes
in 22 patients, >30 minutes in 19 patients, and not evalu-
able in 1 patient. The identifled causes of BTcP are listed
in Table 2. Fifty-lour patients were using analgesics for
BTcP. Analgesics used for pain flares are reported
in Table 4. The satisfaction with BTcP medication was
good in 3 patients, acceptable in 13 patients, and poor in 38
patients.
The causes of BTcP alter analgesic optimization (T1)
are described in Table 3. The mean background pain
intensity was 1.7 (SD + 1.2). The difference in comparison
with T0 was significant (P < 0.0005). Thirty-seven of 6l
patients (55.2%) had BTcP episodes. The difference with T0
was significant (P < 0.0005). In this group of patients, the
mean background pain intensity was 2.2 (SD * 0.9). The
mean pain intensity of BTcP was 7.1 (SD + 1.0). Fifteen
patients had I episode per day, 17 patients had 2 episodes
per day, 4 patients had 3 episodes per day, and I patient
had 4 episodes per day. The onset was < 1 minute in 7
patients, 1 to 5 minutes in 24 patients, 5 to 10 minutes in 4
patients, and > 10 minutes in 2 patients. The duration ol
BTcP was < 5 minutes in 6 patients, 5 to 10 minutes in 20
patients, 10 to 30 minutes in 8 patients, and > 30 minutes in
3 patients. Analgesics used for pain flares are reported
in Table 4. The level of sàtisfaction with BToP medication
was good (23 patients) or very good (13 patients) and
TABLE 1. Epidemiological Characteristics of Patients
Patients surveyed
Patients selected
Age (mean) (y)
Sex (male/lemales)
Karnofsky status (mean)
Primary tumor (n [%])
Pancreas
Colon
Liver
Genitourinary
Others
105
10'7
109
113
115
1t7
119
522
100
65.3 (SD + 11.4)
45/55
47.7 (SD r 11.1)
32 (32)
le (1e)
11 (il)
11 (11)
27 (27)
121
t23
125
121
129
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TABLE 2, Analgesics Used for Background Analgesia
3
5
Analgesic Drugs
T1TO
Mean Doses (+ SD) (me) n Mean Doses (* SD) (me)
Transdermal fentanyl
CO-PA
Tramadol
Oxycodone-naloxone
Oxycodone
Oxycodone-paracetamol
Hydromorphone
Paracetamol
Oral morphine
Transdermal buprenorphine
Transdermal fentanyl-morphine
Tapentadol
Hydromorphone-morphine
CO-PA + OX.NA
CO-PA + oxycodone
Parenteral morphine
OX-NA + paracetamol
Tramadol-NSAIDs
Tramadol-paracetamol
NSAIDS
67
69
7r
73
15
71
79
81
83
85
87
2
9
2
6
I
l3
l0
4
9
4
I
2
1
2
1
I
2
1.6 (+ 1.4)
r1l (r 40.0)
81.2 (+ 33.1)
33.9 (r 19.3)
40 (+ 23.1)
60
32 (+.22.6)
3000
350 (+ 70.7)
1 80/20
90120
15 (+ 7.1)
25
4
f
1
8
l.l (+ 1.2)
43.7 (+ 26.9)
40 (+ 20.0)
20
52.0 (È 83.6)
70.0 (+ 28.2)
0.7 (r 0.3)
241.7 (t t68.6)
)41)4
11
13
15
t'7
19
89
2t
I5
25
27
CO-PA indicates codeine-paracetamol; NSAIDs, nonsteroidal anti-inflammatory drugs; OX-NA, oxycodone-naloxone.
acceptable in one patient. The difference in comparison
with T0 was significant (P < 0.0005).
DlscussroN
Although incident pain associated with bone meta-
stases has been commonly recognized as one of the most
relevant type of BTcP and its incident factors, like nfóve-
ment or burden, are well established,8'e abdominal BTcP
has never been categorized. In this study, the characteristics
of patients with abdominal cancer disease were assessed.
Moreover, we tried to distinguish the epidemiology ol this
event as a possible condition of undertreatment, such as it
was expected at admission, and after optimizing the back-
ground analgesia. The findings were quite interesting.
Although some temporal characteristics, such as onset and
duration, resemble data reported for BTcP observed in
general population,lrl4 causes and frequency of BTcP were
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TABLE 3. ldentified Causes of BTcP at T0 and Tl (See Text)
Idiopathic-possibly UT
Possibly UT
Idiopathic-possibly UT-eating
Idiopathic-possibly UT-supine position
Idiopathic-possibly UT-deambulation
Idiopathic-possibly UT-visceromegaly
Idiopathic
Idiopathic * deambulation
Idiopathic -f orthostatism
Idiopathic f constipation
Idiopathìc * eating
Possibly UT * deambulation
Possibly UT * sitting position
Possibly UT * defecation--eating
Possibly UT * eating
BTcP indicates breakthrough cancer pain; UT. undertreatment.
quite diflerent, at least at admission, when patients were
likely to be undertreated.
Many epidemiological studies of BTcP are inlerred by
the inclusion of patients with uncontrolled background
pain or receiving inadequate basal analges;u.r'10-14 go*-
ever, according to the prevalent definitions,l-5 end of dose
failure or undertreatment should be excluded, per defi-
nition, as a cause of BTcP.6'15 The need to reassess patients
after achieving a good background analgesia is of para-
mount importance in such epidemiological studies, as
reported in a previous survey where a decrease in BTcP
frequency was observed after adequate analgesia was
obtained by a carelul dose titration of opioids.l6 This is
confirmed by the finding ol this study where the lrequency
of BTcP significantly decreased alter optimization ol
background analgesia, also changing the pattern of lactors
identified as triggers for BTcP by patients, leaving the idi-
opathic nature ol BTcP as the leading cause.
Another controversial point is the duration of episodes
of.BTcP, olten reported in the literature. Although it is
possible to measure this parameter in patients with
untreated BTcP, after adequate training, patients take their
medication for BTcP, dnd duration of BTcP becomes
dependent on the onset of the analgesic medication, rather
than the natural duration of the BTcP. For this reason, we
did not report the duration after optimization ol basal
therapy when it is expected that patients receive adequate
medications as needed.
The amount of opioids for background pain and the
appropriateness of drugs administered for BTcP sig-
nificantly changed in comparison with drugs received
belote admission, which often included nonopioid drugs or
opioids for moderate pain. After a comprehensive approach
in an acute ward, patients were receiving higher doses of
opioids lor background analgesia, as well as more rapid
onset opioids lor BTcP, which should be considered the
goal standard because of their capacity to overlap an epi-
sode ol BTcP for both onset and duration, irrespective of
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TABLE 4. Analgesic Drugs Used for BTcP at T0 and Tl
67
69
71
73
75
17
'79
81
83
85
22
5
8
4
2
4
I
2
2
ll
l3
l5
T7
Anti-infl ammatory drugs-paracetamol
Codeine-paracetamol
OTFC
FBT
FNS
Oxycodone-paracetamol
SLF
PFNS
Antispasmodics
Oral morphine
Parenteral morphine
Oral morphine
Oxycodone-naloxone
Tramadol
30/500 mg
200-800 pg
100-800 pg
100-400 pg
5mg
200 pg
200 pg
2^g
l0-l4mg
20 mg
3
9
2
200-600 pg
I 00-2000 pg
100 pg
1 00-400 pg
I 00-400 pg
l5-50 mg
2-15mg
6- l0 mg
50
8
4
I
2
1
2
4
3
19 BTcP indicates breakthrough cancer pain; FBT, fentanyl buccal tablet; FNS, fentanyl nasal spray; OTFC, oral transmucosaÌ lèntanyl citrate; pFNS, pectin
fentanyl nasal spray; SLF, sublingual fentanyl.
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their cost.ls,l7 In fact, the level of satisfaction with regard to
pain medication for BTcP significantly improved.
It has been anecdotally reported that transient visceral
pains initiated by volitional activity may benefit from pre-
emptive therapies or specific therapies targeted at the
underlying mechanisms.ls Oral opioids have been proposed
to be administered about 30 minutes belore the pain is
triggered by a predictable pain trigger,le for example, eating
in patients with pancreatic cancer pain.20 According to the
finding of this study, this clinical feature is often associated
with an analgesic undertreatment and tends to disappear
after optimization of background analgesia.l0 In a con-
comitant study performed in a general population, inclf,d-
ing all cancers and not only abdominal pain distribution,
the same approach was effective in reducing the number,
duration, and intensity of BTcP but was unable to change
the prevalence of BTcP.2l
Limitations of the study are linked to the lack of a
controlled design and the number of patients enrolled in the
study. These problems are inherent to many studies of
cancer patients. A placebo effect cannot be excluded,
without any comparison. Hospital stay and the speciflc
setting may in part influence the outcome. This issue is
strongly debated in palliative care, where there is a need for
controlled studies providing the best evidence. In contrast,
a control group is difficult to conceive in the context of
patients' suffering. In this case, patients with uncontrolled
pain would have been treated with a placebo, raising ethical
and practical concerns. For instance, such information
should be considered as preliminary and should be con-
firmed in future studies.
The number of patients recruited may be another
limitation. After conducting the first part of the study, we
were aware of the need to increase the sample size to pro-
vide more consistent information. Of interest, most studies
of BToP, which include a treatment, were approximately
performed in a similar amount of patients. Findings of this
study should be confirmed in larger multicenter studies and
in different settings.
In conclusion, this preliminary study provides new
insights on the characteristics of BTcP in a subclass of
patients with abdominal disease. It has been estimated that
about 55% of patients with well-controlled background
4 I www,clinicalpain.com
pain will develop BTcP episodes, which positively respond
to an individualized treatment. This percentage was higher
(about 90%) in patients who presented with uncontrolled
background pain, underlying the need to better characterize
patients with BToP, only after a careful optimization of
basal pain, as considered by the definition of BTcP.
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